Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Withdrawn 1Recruiting 1Available 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Endocrine 11NET 3Sarcoma 2Gastrointestinal 2Other hematologic neoplasm 1Lymphoid 1Head & Neck 1CNS 1

Conditions

Neuroendocrine Tumors 531Gastro-enteropancreatic neuroendocrine tumor 58Carcinoid Tumor 58Neoplasms 49Carcinoma, Neuroendocrine 44Pancreatic Neoplasms 36Adenoma, Islet Cell 33Neoplasm Metastasis 28Pheochromocytoma 25Colorectal Neoplasms 24Paraganglioma 23Stomach Neoplasms 21Breast Neoplasms 21Prostatic Neoplasms 20Lung Neoplasms 20Carcinoma, Hepatocellular 20Sarcoma 19Carcinoma 19Thyroid Neoplasms 18Gastrointestinal Neoplasms 18Neuroblastoma 15Cholangiocarcinoma 14Carcinoma, Renal Cell 14Small Cell Lung Carcinoma 13Melanoma 13Esophageal Neoplasms 13Serotonin Syndrome 12Colonic Neoplasms 12Brain Neoplasms 11Adenocarcinoma 11

Interventions

pasireotide 1Diazoxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Hypoglycemia × NET × Clear all
NCT06881992 2026-05-18

Tumor HI

Rezolute

Phase 3 Recruiting
16 enrolled
EndocrineNETSarcoma

Fibrosarcoma, Hyperinsulinism, Hypoglycemia, Insulinoma, Adenoma, Islet Cell, Liposarcoma, Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT07262970 2025-12-04

Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor

Rezolute

Available
EndocrineNETSarcoma

Fibrosarcoma, Hyperinsulinism, Hypoglycemia, Insulinoma, Adenoma, Islet Cell, Liposarcoma, Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT02779257 2022-03-04

Pasireotide Treatment for Neuroendocrine Tumor

University of Maryland, Baltimore

Phase 4 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Hypoglycemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡